US Saves $313bn From Generics And $2.2bn From Biosimilars
AAM’s Annual Report Focuses On Patient & Stakeholder Benefits
Executive Summary
The AAM’s 2019 report titled ‘Securing Our Access & Savings’ throws light on the monumental savings and benefits of generics and biosimilars for US patients and other stakeholders. The report urges policymakers to act to address obstacles to the off-patent industry and brings industry’s COVID-19 response in perspective again.
You may also be interested in...
Bourdage Sets Out Sandoz’ Biosimilar Growth Ambitions
Sandoz plans to add at least one new molecule per year to its biosimilar development plans, while still maintaining a “selective” approach to targets, head of biopharmaceuticals Pierre Bourdage explains in the second part of an exclusive interview with Generics Bulletin.
Sandoz Aims To Be ‘First In And Last Out’ In North America
Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.
Biden Administration Urged To Prioritize Sustainable Access
The AAM has unveiled its policy priorities for sustainable access to generics and biosimilars for the newly elected US president Joe Biden’s administration and the 117th Congress. The association has also launched a new advocacy campaign called “Secure Our Meds,” kicking off with a report on “Securing Sustainable Markets.”